Profund Advisors LLC Raises Stake in Celldex Therapeutics, Inc. $CLDX

Profund Advisors LLC grew its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 99.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,454 shares of the biopharmaceutical company’s stock after purchasing an additional 21,149 shares during the quarter. Profund Advisors LLC owned approximately 0.06% of Celldex Therapeutics worth $1,153,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CLDX. Vestal Point Capital LP boosted its stake in shares of Celldex Therapeutics by 781.0% during the second quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $35,612,000 after purchasing an additional 1,551,354 shares during the period. Braidwell LP purchased a new stake in shares of Celldex Therapeutics during the third quarter valued at $15,307,000. Wellington Management Group LLP boosted its stake in shares of Celldex Therapeutics by 10.8% during the third quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock valued at $150,046,000 after purchasing an additional 567,677 shares during the period. Eventide Asset Management LLC lifted its stake in Celldex Therapeutics by 37.1% in the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after acquiring an additional 502,909 shares during the period. Finally, Millennium Management LLC lifted its stake in Celldex Therapeutics by 104.3% in the third quarter. Millennium Management LLC now owns 975,195 shares of the biopharmaceutical company’s stock worth $25,228,000 after acquiring an additional 497,968 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CLDX. Stifel Nicolaus reaffirmed a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Wells Fargo & Company upped their price objective on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Monday, April 20th. Finally, Barclays upped their price objective on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $49.78.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $30.58 on Friday. The company has a market capitalization of $2.40 billion, a PE ratio of -7.18 and a beta of 0.98. The company has a 50-day simple moving average of $32.00 and a two-hundred day simple moving average of $28.21. Celldex Therapeutics, Inc. has a one year low of $18.55 and a one year high of $35.79.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.80 million. On average, equities analysts predict that Celldex Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.